Cargando…

Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa

Detalles Bibliográficos
Autores principales:	Gray, Glenda, Collie, Shirley, Goga, Ameena, Garrett, Nigel, Champion, Jared, Seocharan, Ishen, Bamford, Lesley, Moultrie, Harry, Bekker, Linda-Gail
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Massachusetts Medical Society 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9093716/ https://www.ncbi.nlm.nih.gov/pubmed/35507482 http://dx.doi.org/10.1056/NEJMc2202061

Ejemplares similares

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
por: Collie, Shirley, et al.
Publicado: (2021)

Effectiveness and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South Africa
por: Collie, Shirley, et al.
Publicado: (2022)

Breakthrough SARS-CoV-2 infections during periods of delta and omicron predominance, South Africa
por: Goga, Ameena, et al.
Publicado: (2022)

Vascular thrombosis after single dose Ad26.COV2.S vaccine in healthcare workers in South Africa: open label, single arm, phase 3B study (Sisonke study)
por: Jacobson, Barry Frank, et al.
Publicado: (2023)

High Rate of Asymptomatic Carriage Associated with Variant Strain Omicron
por: Garrett, Nigel, et al.
Publicado: (2022)

High Asymptomatic Carriage With the Omicron Variant in South Africa
por: Garrett, Nigel, et al.
Publicado: (2022)

Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial
por: Takuva, Simbarashe, et al.
Publicado: (2022)

Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study
por: Takuva, Simbarashe, et al.
Publicado: (2021)

Allergic reactions to the Ad26.COV2.S vaccine in South Africa
por: Peter, Jonny, et al.
Publicado: (2021)

Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study
por: Bekker, Linda-Gail, et al.
Publicado: (2022)

BNT162b2 Protection against the Omicron Variant in Children and Adolescents
por: Price, Ashley M., et al.
Publicado: (2022)

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
por: Cele, Sandile, et al.
Publicado: (2021)

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2022)

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection
por: Nemet, Ital, et al.
Publicado: (2021)

BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

Fourth BNT162b2 vaccination neutralization of omicron infection after heart transplantation
por: Peled, Yael, et al.
Publicado: (2022)

Effectiveness of the third dose of BNT162b2 vaccine on neutralizing Omicron variant in the Japanese population()
por: Kawasuji, Hitoshi, et al.
Publicado: (2022)

Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age
por: Tan, Sharon H.X., et al.
Publicado: (2022)

BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age
por: Cohen-Stavi, Chandra J., et al.
Publicado: (2022)

Neutralizing antibody titers to Omicron six months after vaccination with BNT162b2 in Colombia
por: Zapata-Cardona, María I., et al.
Publicado: (2022)

Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
por: Choi, Seong-Ho, et al.
Publicado: (2023)

Limited Neutralization of Omicron by Antibodies from the BNT162b2 Vaccination against SARS-CoV-2
por: Lanz, Tobias V., et al.
Publicado: (2022)

Antibody levels after BNT162b2 vaccine booster and SARS-CoV-2 Omicron infection
por: Vietri, Maria Teresa, et al.
Publicado: (2022)

Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2
por: Xia, Hongjie, et al.
Publicado: (2022)

Immunocompromise and durability of BNT162b2 vaccine against severe outcomes due to omicron and delta variants
por: Tartof, Sara Y, et al.
Publicado: (2022)

Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
por: Cerqueira-Silva, Thiago, et al.
Publicado: (2022)

Protective antibodies and T cell responses to Omicron variant after the booster dose of BNT162b2 vaccine
por: Naaber, Paul, et al.
Publicado: (2022)

Effect of vaccine dosing intervals on Omicron surrogate neutralization after three doses of BNT162b2
por: Prusinkiewicz, Martin A., et al.
Publicado: (2023)

Ad26.COV2.S boosts antibody and T-cell responses following BNT162b2 vaccination
por: Iketani, Sho, et al.
Publicado: (2021)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Diminished T-cell immune responses to SARS-CoV-2 omicron variant after BNT162b2 vaccination
por: Jordan, Stanley C., et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera
por: Muik, Alexander, et al.
Publicado: (2022)

BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5
por: Tartof, Sara Y, et al.
Publicado: (2022)

Omicron sublineage recombinant XBB evades neutralising antibodies in recipients of BNT162b2 or CoronaVac vaccines
por: Zhang, Xiaojuan, et al.
Publicado: (2023)

Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years
por: Winokur, Patricia, et al.
Publicado: (2023)

Effectiveness of BNT162b2 and CoronaVac vaccines against omicron in children aged 5 to 11 years
por: Oliveira, Eduardo A., et al.
Publicado: (2023)

Effectiveness of Ad26.COV2.S Vaccine vs BNT162b2 Vaccine for COVID-19 Hospitalizations
por: Botton, Jérémie, et al.
Publicado: (2022)

Reduced neutralization of SARS-CoV-2 Omicron variant by BNT162b2 vaccinees’ sera: a preliminary evaluation
por: Mileto, D., et al.
Publicado: (2022)

Breakthrough infections with SARS-CoV-2 omicron efficiently boost antibodies from previous BNT162b2 vaccinations
por: Perkmann, Thomas, et al.
Publicado: (2023)

Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster Vaccination
por: Pedersen, Rune M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u0bdv95828l1ebmeihj5pnpdkv